What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?

Olthoff, Kim M.; Forner, Alejandro; Hübscher, Stefan G.; Fung, John J.

doi:10.1002/lt.22352

Cited by 19 publications

(9 citation statements)

References 63 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs detection in HCC patients has been reported in several studies [67,68] . The numbers of CTCs were closely correlated with portal vein thrombosis, tumor infiltration, prognosis and Child-Pugh grade [61,64,69] .…”

Section: Ctcsmentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, "liquid biopsy", in the management of HCC patients.

show abstract

Section: Ctcsmentioning

confidence: 99%

Performance of different biomarkers for the management of hepatocellular carcinoma

Rojas¹,

Sánchez‐Torrijos²,

Gil‐Gómez³

et al. 2018

View full text Add to dashboard Cite

show abstract

“…An average of 19 ± 24 CTCs were detected in 5 ml of patient blood samples, and the positive rate and number of CTCs correlated significantly with Table 1 Key points of this concise review. Conclusions and perspectives the tumor size, portal vein cancerous thrombus formation and the TNM (tumor-node-metastasis) stage, although the TNM system poorly predicts the prognosis in HCC patients [20]. The clinical value of this method requires further verification with other commonly used markers, such as epithelial cell adhesion molecule (EpCAM), in a prospective clinical trial with a large number of cases.…”

Section: Isolation Of Ctcs With Immunomagnetic Beadsmentioning

confidence: 99%

Capturing circulating tumor cells of hepatocellular carcinoma

Wu¹,

Pan²,

Pei³

et al. 2012

Cancer Letters

View full text Add to dashboard Cite

a b s t r a c tEarly metastases of hepatocellular carcinoma (HCC) may be detected by the isolation of circulating tumor cells (CTCs) in the bloodstream. During the course of therapeutic attempts, monitoring CTC changes in patients with HCC is helpful for the efficacy assessment. Nevertheless, the markers used for the detection, such as a-feto protein, asialoglycoprotein receptor or epithelial cell adhesion molecule, CD133 or CD90, are not specific for HCC CTCs. In spite of these limitations, a timely determination of the existence of CTCs will be beneficial for the monitoring of distant metastases, the evaluation of therapeutic attempts, and the prediction of prognosis.

show abstract

“…To assess the prognosis of all HCC patients, the best staging system should take into account tumor stage, liver function, and physical status. 101 In addition, the prognosis should be modified according to the treatment. There is no worldwide consensus about the use of any HCC staging system for all HCC patients, and the systems vary significantly by country.…”

Section: Staging and Of Hepatocellular Carcinoma (Hcc) And Treatment mentioning

confidence: 99%

“…The Barcelona-Clinic Liver Cancer (BCLC) and CLIP staging systems are used most frequently in Europe, whereas the JIS system has been accepted as a standard in Japan. 101 The BCLC staging has been widely used as the standard means of assessing the prognosis for patients with HCC. 5 The BCLC classification, which was introduced in 1999 102 and subsequently updated 53 is the only system that links the prognosis with treatment recommendations (Figure 2).…”

Section: Staging and Of Hepatocellular Carcinoma (Hcc) And Treatment mentioning

confidence: 99%

The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations

Kumar

Acharya

Singh

et al. 2014

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?

Cited by 19 publications

References 63 publications

Performance of different biomarkers for the management of hepatocellular carcinoma

Performance of different biomarkers for the management of hepatocellular carcinoma

Capturing circulating tumor cells of hepatocellular carcinoma

The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations

Contact Info

Product

Resources

About